http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Tunyaporn Jongudomsombat ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Tunyaporn Jongudomsombat ),( Jemin Kim ),( Young In Lee ),( Jihee Kim ),( Ju Hee Lee ) 대한피부과학회 2020 대한피부과학회 학술발표대회집 Vol.72 No.1
Background: The concomitant use of oral isotretinoin with laser or energy-based intervention could be effective way to treat patients with moderate-to-severe inflammatory acne lesions. Still, studies regarding their efficacy and safety are limited. Objectives: To assess the efficacy and the safety of systemic isotretinoin with laser or energy-based interventions in patients with inflammatory acne. Methods: We performed a retrospective cohort study of patients with inflammatory acne who had been prescribed oral isotretinoin for more than 3 months, with or without concomitant laser interventions. Clinical characteristics, Modified Global Acne Grading Score (mGAGS), Global Improvement Score (GIS), side effects of the treatment, recurrence rate were assessed. Results: Of the total 122 patients, 83 (68%) were received concomitant laser and oral isotretinoin treatment, and 39 (32%) were treated with oral isotretinoin only. Over the one year of treatment duration, a significant difference in the reduction of mGAGS between two groups was noted with RM-ANOVA analysis. Also, drug-related side effects and recurrence rates after treatment were lower in the concomitant treatment group than the oral isotretinoin group. Conclusion: The concomitant use of oral isotretinoin with laser or energy-based intervention is an effective and safe treatment modality for inflammatory acne patients.
-
( Jemin Kim ),( Tunyaporn Jongudomsombat ),( Young In Lee ),( Jihee Kim ),( Ju Hee Lee ) 대한피부과학회 2020 대한피부과학회 학술발표대회집 Vol.72 No.1
Background: Tranilast, N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), which was initially identified as an anti-allergic agent, is also known to have anti-fibrotic potential by inhibiting the proliferation of fibroblasts and collagen deposition. Previous clinical studies on the efficacy and safety of systemic treatment of tranilast on fibrotic skin diseases, such as keloid or hypertrophic scar, are limited. Objectives: To evaluate the safety and efficacy of oral tranilast in treatment of keloid scars Methods: We performed a retrospective observational study of patients with keloids who had been prescribed oral tranilast for more than 3 months. Scar improvement and patient satisfaction were assessed using the Vancouver Scar Scale (VSS) score and the 5-point patient self-assessment score. Any side effects including abnormality in routine lab tests during the treatment period were noted. Results: Of the 42 patients, 27 (64.3%) were female. The mean duration of prescription was 115 days. Significant improvement of total VSS (9.50 vs. 5.62, p<0.001) was noted, along with the subjective improvement of patient-reported symptoms. There was no specific drug-related side effect, and the laboratory tests revealed no significant change. Conclusion: Our study showed that oral tranilast is and effective and well-tolerated treatment for keloid scar. Optimization of treatment with other therapeutic modalities is necessary to develop a more standardized treatment protocol.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
